MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables episode artwork

EPISODE · Mar 5, 2021 · 11 MIN

MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables

from MPR Weekly Dose

This week we have news of an indication for the cancer treatment, Keytruda, being withdrawn; Janssen's single dose vaccine gains Emergency Authorization; There's findings on the effectiveness of Ivermectin as a therapy for mild COVID-19; And devices to treat migraine and prevention of sub-concussive head impacts are authorized for marketing.

Episode metadata supplied by the publisher feed · Published Mar 5, 2021

Embed this episode

Ready to play

MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables

0:00 11:48

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 11 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on March 5, 2021.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!